Efinopegdutide
Aliases: HM15211 · GLP-1/GCGR dual agonist
Efinopegdutide is a linear peptide targeting GLP-1R, Glucagon receptor, developed by Eli Lilly for undisclosed indications. As of Aug 15, 2024, its highest verified stage is Phase 2.
Phase 2· verified Aug 15, 2024
Identity
- Generic name
- efinopegdutide
- Brand names
- —
- Development codes
- HM15211
- Sponsor / originator
- Eli Lilly
- Targets
- GLP-1RGlucagon receptor
- Route / formulation
- Subcutaneous injection
Development timeline
Trials
View all →No records found.